Drug Trial Radar · NCT04072640
Three Induction Treatments on Cryptococcal Meningitis
Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 25, 2021
Primary completion
Jul 31, 2022
Study completion Dec 1, 2022
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wenzhou Central Hospital
- First posted
- Aug 28, 2019
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Three induction treatment strategies \[ voriconazole +5FC vs. amphotericin deoxycholate (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC \] for HIV-infected patients with cryptococcal meningitis were compared.
Conditions
- Cryptococcal Meningitis
- HIV/AIDS
Interventions
Voriconazole 200mgDrug
Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
amphotericin B deoxycholate (0.4-0.5mg/kg/d)Drug
Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)Drug
Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- 90-day Cryptococcal Meningitis (CM) related mortalityTime frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lijun Xu
Zhenjiang, Hangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.